Warren Lee, PA
Medical · Champaign, ILNPI 1487661955
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,073 of the $11,312 with a category attached, or 89.0%. It is spread thinly across 26 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,322, 3.4 times the $983 reported in 2021. Among medical clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 504 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Mayne Pharma Commercial LLC$1K
- Johnson & Johnson$964
- Lilly USA, LLC$774
- Dermavant Sciences, Inc.$586
- Pfizer$565
- plus $5K from 20 others
What the payments were for
- Consulting fees$6195%
- Food & beverage$10,07389%
- Education$6215%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $2,456 |
| Mayne Pharma Commercial LLC | 62 | $1,208 |
| Johnson & Johnson | 44 | $964 |
| Lilly USA, LLC | 43 | $774 |
| Dermavant Sciences, Inc. | 25 | $586 |
| Pfizer | 38 | $565 |
| Regeneron Healthcare Solutions, Inc. | 21 | $545 |
| Sanofi | 18 | $512 |
| E.r. Squibb & Sons, L.L.C. | 26 | $430 |
| Organon | 12 | $408 |
| UCB, Inc. | 17 | $362 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 17 | $336 |
| Arcutis Biotherapeutics, Inc. | 18 | $326 |
| Novartis | 16 | $320 |
| Incyte Corporation | 13 | $319 |
| Amgen | 10 | $222 |
| Galderma Laboratories, L.p. | 7 | $215 |
| LEO Pharma Inc. | 8 | $184 |
| Almirall LLC | 2 | $171 |
| Sun Pharmaceutical Industries Inc. | 8 | $161 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Journey Medical Corporation | 2 | $48 |
| Genentech USA, Inc. | 2 | $33 |
| Sandoz | 2 | $32 |
| Boehringer Ingelheim | 1 | $28 |
| Botanix SB Inc | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,312 in reported general payments places this provider in the 95th percentile of 449 medical providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 48 | $978,414 |
| Humira(Cf) PenAdalimumab | 74 | $882,115 |
| Dupixent PenDupilumab | 145 | $580,138 |
| OtezlaApremilast | 81 | $381,800 |
| SkyriziRisankizumab-Rzaa | 11 | $237,951 |
| StelaraUstekinumab | 11 | $190,673 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 26 | $185,869 |
| Taltz AutoinjectorIxekizumab | 24 | $157,845 |
| RinvoqUpadacitinib | 19 | $117,653 |
| Enbrel MiniEtanercept | 13 | $93,686 |
| SiliqBrodalumab | 13 | $67,440 |
| Dupixent SyringeDupilumab | 13 | $47,671 |
| Clobetasol Propionate | 558 | $24,685 |
| Tacrolimus | 103 | $22,859 |
| Doxycycline Hyclate | 272 | $8,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $222 | $381,80081 claims |
| AbbVieSkyrizi, Rinvoq | $2,456 | $355,60430 claims |
| Johnson & JohnsonStelara | $964 | $190,67311 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq | $336 | $67,44013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 449 medical providers in Illinois.
Other medical in Champaign
- Janice JonesChampaign$4K
- Andrea TurekChicago$145K
- Priya BediElmhurst$56K
- Jennifer GarsonChicago$32K
- Bernice JohnsonPalos Heights$32K
- William KvasnickaChicago$19K
- Katie SpringerLake Forest$17K
- Matthew BrunoMorris$17K
- Kelly BrawleyBarrington$14K
- Megan GriggsSpringfield$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.